Compugen

Compugen company information, Employees & Contact Information

Explore related pages

Related company profiles:

Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company Details

Employees
110
Address
Tel Aviv, Israel, Il
Phone
+972 3-765-8585
Email
jo****@****gen.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Tel Aviv, Israel
Looking for a particular Compugen employee's phone or email?

Compugen Questions

News

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025 - Yahoo Finance

Compugen to Release Third Quarter 2025 Results on Monday, November 10, 2025 Yahoo Finance

Compugen (NASDAQ: CGEN) schedules third quarter results Nov 10; call 8:30 ET - Stock Titan

Compugen (NASDAQ: CGEN) schedules third quarter results Nov 10; call 8:30 ET Stock Titan

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 - Yahoo Finance

Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 Yahoo Finance

First-in-Human COM503 Trial — Compugen to Present Poster at SITC Nov 7, 2025 in National Harbor - Stock Titan

First-in-Human COM503 Trial — Compugen to Present Poster at SITC Nov 7, 2025 in National Harbor Stock Titan

Compugen: Immuno-Oncology Innovator Poised For A Comeback (NASDAQ:CGEN) - Seeking Alpha

Compugen: Immuno-Oncology Innovator Poised For A Comeback (NASDAQ:CGEN) Seeking Alpha

Earnings call transcript: Compugen Q2 2025 sees revenue miss, EPS surprise - Investing.com

Earnings call transcript: Compugen Q2 2025 sees revenue miss, EPS surprise Investing.com

Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation? - simplywall.st

Is There An Opportunity With Compugen Ltd.'s (NASDAQ:CGEN) 33% Undervaluation? simplywall.st

60 Evaluable Patients: Compugen COM701 Pooled Analysis Demonstrates Durable Responses in PROC; Poster Oct 18 - Stock Titan

60 Evaluable Patients: Compugen COM701 Pooled Analysis Demonstrates Durable Responses in PROC; Poster Oct 18 Stock Titan

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Yahoo Finance

Compugen to Present at the H.C. Wainwright 27th Annual Global Investment Conference Yahoo Finance

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer - PR Newswire

Compugen Announces Appointment of Michelle Mahler M.D. as Chief Medical Officer PR Newswire

Has Compugen Ltd.'s (NASDAQ:CGEN) Impressive Stock Performance Got Anything to Do With Its Fundamentals? - simplywall.st

Has Compugen Ltd.'s (NASDAQ:CGEN) Impressive Stock Performance Got Anything to Do With Its Fundamentals? simplywall.st

AI-Powered Cancer Discovery: Compugen to Showcase Breakthrough Spatial Transcriptomics Research in Sweden - Stock Titan

AI-Powered Cancer Discovery: Compugen to Showcase Breakthrough Spatial Transcriptomics Research in Sweden Stock Titan

AI-Powered Cancer Immunotherapy Pioneer Compugen to Present at H.C. Wainwright Investment Conference - Stock Titan

AI-Powered Cancer Immunotherapy Pioneer Compugen to Present at H.C. Wainwright Investment Conference Stock Titan

Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts - Yahoo Finance

Compugen Ltd. (CGEN): Among the Penny Stocks With Huge Upside Potential According to Analysts Yahoo Finance

Compugen (NASDAQ:CGEN) shareholder returns have been stellar, earning 204% in 1 year - simplywall.st

Compugen (NASDAQ:CGEN) shareholder returns have been stellar, earning 204% in 1 year simplywall.st

Revolutionary AI Platform Reveals New Cancer Treatment Pathways: Compugen to Present Groundbreaking Research - Stock Titan

Revolutionary AI Platform Reveals New Cancer Treatment Pathways: Compugen to Present Groundbreaking Research Stock Titan

Compugen Q2 Earnings: $94M Cash Runway Powers Multiple Cancer Drug Trials, ESMO Data Coming - Stock Titan

Compugen Q2 Earnings: $94M Cash Runway Powers Multiple Cancer Drug Trials, ESMO Data Coming Stock Titan

Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates - Yahoo Finance

Compugen (CGEN) Reports Q2 Loss, Lags Revenue Estimates Yahoo Finance

Breakthrough Immunotherapy Trial Launches for Platinum-Sensitive Ovarian Cancer Treatment - Stock Titan

Breakthrough Immunotherapy Trial Launches for Platinum-Sensitive Ovarian Cancer Treatment Stock Titan

Compugen Announces Leadership Transitions Effective September 2025 - Stock Titan

Compugen Announces Leadership Transitions Effective September 2025 Stock Titan

Compugen Ltd (CGEN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - Yahoo Finance

Compugen Ltd (CGEN) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline Yahoo Finance

Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance

Compugen Ltd (CGEN) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges Yahoo Finance

Compugen Ltd. (NASDAQ: CGEN) is One of Tuesday Morning’s Most Active Stocks - FinancialContent

Compugen Ltd. (NASDAQ: CGEN) is One of Tuesday Morning’s Most Active Stocks FinancialContent

FDA Clears COM503 IND in Solid Tumors, Phase 1 Trial Anticipated - Targeted Oncology

FDA Clears COM503 IND in Solid Tumors, Phase 1 Trial Anticipated Targeted Oncology

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program - Business Wire

Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program Business Wire

Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically - simplywall.st

Analysts Just Shaved Their Compugen Ltd. (NASDAQ:CGEN) Forecasts Dramatically simplywall.st

Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development - PR Newswire

Compugen Announces Appointment of Dr. Oliver Froescheis as Senior Vice President, Corporate and Business Development PR Newswire

Hill Wallack: Trenton Move Fizzles Out - communitynews.org

Hill Wallack: Trenton Move Fizzles Out communitynews.org

CGEN Stock Price and Chart — NASDAQ:CGEN - TradingView

CGEN Stock Price and Chart — NASDAQ:CGEN TradingView

Top Compugen Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant